Matinas BioPharma Holdings Inc - ESG Rating & Company Profile powered by AI
Alternative corporations in the scoring industry group for Matinas BioPharma Holdings Inc are shown below. This analysis of Matinas BioPharma Holdings Inc employs data points from across the web as well as from available documents by Matinas BioPharma Holdings Inc. Jump to the bottom of this webpage for potential risks for Matinas BioPharma Holdings Inc based on industry, location and marketcap.
Matinas BioPharma Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 4.0, social score of 4.0 and governance score of 5.7.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1121 | Protagonist Therapeutics Inc | 4.8 | High |
| 1121 | Shanghai Medicilon Inc | 4.8 | High |
| 1156 | Matinas BioPharma Holdings Inc | 4.7 | High |
| 1156 | Albireo Pharma Inc | 4.7 | High |
| 1156 | Adaptimmune Therapeutics PLC | 4.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Matinas BioPharma Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc report the average age of the workforce?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc offer flexible work?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc conduct supply chain audits?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose water use targets?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Matinas BioPharma Holdings Inc have a product recall in the last two years?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Matinas BioPharma Holdings Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose parental leave metrics?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Matinas BioPharma Holdings Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose its waste policy?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc report according to TCFD requirements?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose energy use targets?
Sign up for free to unlockDoes Matinas BioPharma Holdings Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Matinas BioPharma Holdings Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Matinas BioPharma Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.